8-K: Edwards Lifesciences Reports Strong Q4 and Full Year 2023 Results, Confident in 2024 Outlook

Edwards Lifesciences announced a 14% increase in fourth-quarter sales and a 12% increase in full-year sales, driven by growth across all product groups and the early FDA approval of EVOQUE.

Summary

• Edwards Lifesciences reported a 14% increase in sales for the fourth quarter of 2023, reaching $1.53 billion, with constant currency sales growth of 13%.
• Full-year 2023 sales totaled $6.0 billion, a 12% increase year-over-year on both a reported and constant currency basis.
• The company's fourth-quarter earnings per share (EPS) were $0.61, with an adjusted EPS of $0.64.
• For the full year, diluted EPS was $2.30, and adjusted EPS was $2.51.
• Transcatheter Aortic Valve Replacement (TAVR) sales grew 13% in the fourth quarter, reaching $979 million, with constant currency growth of 12%.
• Transcatheter Mitral and Tricuspid Therapies (TMTT) sales were $56 million for the quarter, and full-year sales grew more than 65% on a constant currency basis to $198 million.
• Surgical Structural Heart sales grew 11% to $248 million, and Critical Care sales grew 11% to $250 million in the fourth quarter.
• The company completed a $400 million accelerated share repurchase in Q4, bringing the total repurchased in 2023 to $867 million.
• Edwards is confident in its 2024 guidance, projecting 8 to 10% constant currency sales growth and adjusted EPS of $2.70 to $2.80.
• The company expects full year 2024 sales to be between $6.3 and $6.6 billion.
• For the first quarter of 2024, the company projects total sales to be between $1.53 and $1.61 billion, and adjusted EPS of $0.62 to $0.66.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong financial results, successful product launches, and optimistic future guidance. The company's confidence in its growth prospects and the early approval of EVOQUE contribute to the positive outlook. However, the decrease in gross profit margin and increased expenses temper the sentiment slightly.

Positives

• Strong sales growth across all product groups, including TAVR, TMTT, Surgical Structural Heart, and Critical Care.
• Successful launch and adoption of the SAPIEN 3 Ultra RESILIA platform.
• Early FDA approval for the EVOQUE system, a groundbreaking treatment for tricuspid regurgitation.
• Positive clinical trial results supporting approvals and adoption of new therapies.
• Strong financial performance with a 12% increase in full-year sales and a 14% increase in Q4 sales.
• The company has a strong cash position with $1.6 billion in cash, cash equivalents, and short-term investments.
• The company is confident in its 2024 guidance and expects continued growth.
• The company has a $1 billion remaining under its current share repurchase authorization.

Negatives

• The adjusted gross profit margin decreased to 76.8% in Q4 2023 from 81.0% in the same period last year, primarily due to foreign exchange impacts.
• Selling, general, and administrative expenses increased to $480 million in Q4, driven by investments in transcatheter field-based personnel.
• Research and development expenses increased by 16% to $270 million in Q4 due to continued investments in transcatheter valve innovations.

Risks

• The company faces risks and uncertainties associated with the spin-off of its Critical Care product group.
• There are risks related to the development of new products and potential manufacturing and quality issues.
• Challenges related to clinical trial or commercial results or new product approvals and therapy adoption could impact the company.
• The company is exposed to the impact of domestic and global economic conditions and competitive dynamics.
• Reliance on vendors, suppliers, and other third parties poses a risk.
• Damage, failure, or interruption of information technology systems could impact operations.
• The company is exposed to product liability claims and the use of its products in unapproved circumstances.
• Changes to reimbursement for the company's products could affect revenue.
• Currency exchange rate fluctuations could impact financial results.
• Unanticipated actions by the U.S. Food and Drug Administration and other regulatory agencies could affect the company.
• Changes to tax laws could impact the company's financial performance.
• Unexpected impacts or expenses of litigation or internal or government investigations could affect the company.

Future Outlook

The company is confident in its 2024 guidance of 8 to 10% constant currency sales growth and adjusted EPS of $2.70 to $2.80. Full year 2024 sales are expected to be between $6.3 and $6.6 billion. The company expects full year 2024 TMTT sales at the higher end of the previous $280 to $320 million guidance range. For the first quarter of 2024, the company projects total sales to be between $1.53 and $1.61 billion, and adjusted EPS of $0.62 to $0.66.

Management Comments

• In 2023, our team made significant progress advancing transformational therapies for patients while delivering strong financial performance, said Bernard Zovighian, Edwards CEO.
• We exited the year with strong momentum driven by our broad portfolio of innovative therapies.
• In 2024, we anticipate launching multiple breakthrough technologies globally and advancing important clinical trials as we embark on a new era of structural heart innovation.
• These breakthroughs, along with significant unmet patient needs, give us confidence in our ability to accelerate growth in 2025 and beyond.

Industry Context

This announcement highlights Edwards Lifesciences' continued leadership in the structural heart disease and critical care monitoring markets. The strong growth in TAVR and TMTT sales reflects the increasing adoption of transcatheter therapies, a trend seen across the medical device industry. The early approval of EVOQUE positions Edwards well in the emerging market for tricuspid regurgitation treatments.

Comparison to Industry Standards

• Edwards' 12% full-year sales growth is strong compared to the overall medical device industry, which has seen more moderate growth.
• The 13% growth in TAVR sales is in line with the growth seen by other major players in the transcatheter valve market, such as Medtronic.
• The 65% growth in TMTT sales is particularly impressive, indicating Edwards' strong position in this emerging market segment.
• The company's focus on innovation, as evidenced by the early approval of EVOQUE and the continued development of the RESILIA tissue platform, is a key differentiator compared to competitors.
• The company's adjusted gross profit margin of 76.8% is relatively high compared to other medical device companies, but the decrease from 81.0% in the prior year is a point of concern.

Stakeholder Impact

• Shareholders will benefit from the strong financial performance and share repurchase program.
• Employees will be impacted by the company's growth and expansion.
• Customers (clinicians and hospitals) will have access to innovative therapies.
• Patients will benefit from the company's focus on developing and providing advanced treatment options.
• Suppliers and creditors will be impacted by the company's financial performance and growth.

Next Steps

• The company plans a disciplined launch of the SAPIEN 3 Ultra RESILIA platform in Europe.
• Edwards will continue to advance important clinical trials.
• The company will launch multiple breakthrough technologies globally in 2024.
• The company will continue to focus on patient activation and expanding the adoption of its therapies.

Key Dates

Keywords

Edwards Lifesciences, TAVR, TMTT, Structural Heart, Critical Care, EVOQUE, SAPIEN 3 Ultra RESILIA, Transcatheter Valve, Medical Devices, Financial Results